CN110755434B - 化合物palosuran防治骨骼肌萎缩等疾病的用途 - Google Patents
化合物palosuran防治骨骼肌萎缩等疾病的用途 Download PDFInfo
- Publication number
- CN110755434B CN110755434B CN201810844111.9A CN201810844111A CN110755434B CN 110755434 B CN110755434 B CN 110755434B CN 201810844111 A CN201810844111 A CN 201810844111A CN 110755434 B CN110755434 B CN 110755434B
- Authority
- CN
- China
- Prior art keywords
- skeletal muscle
- compound
- palosuran
- diabetes
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810844111.9A CN110755434B (zh) | 2018-07-27 | 2018-07-27 | 化合物palosuran防治骨骼肌萎缩等疾病的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810844111.9A CN110755434B (zh) | 2018-07-27 | 2018-07-27 | 化合物palosuran防治骨骼肌萎缩等疾病的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110755434A CN110755434A (zh) | 2020-02-07 |
CN110755434B true CN110755434B (zh) | 2022-03-15 |
Family
ID=69327009
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810844111.9A Active CN110755434B (zh) | 2018-07-27 | 2018-07-27 | 化合物palosuran防治骨骼肌萎缩等疾病的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110755434B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116139140A (zh) * | 2021-11-19 | 2023-05-23 | 中国医学科学院药物研究所 | 一种化合物在治疗糖皮质激素不良反应中的用途 |
CN117482099B (zh) * | 2024-01-03 | 2024-04-09 | 中日友好医院(中日友好临床医学研究所) | 木通皂苷d在制备抗骨骼肌萎缩、肌病药物中的应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1494542A (zh) * | 2001-03-27 | 2004-05-05 | ������˹ҩƷ��˾ | 作为尾加压素ii受体拮抗剂的1,2,3,4-四氢异喹啉的衍生物 |
CN101039930A (zh) * | 2004-10-12 | 2007-09-19 | 埃科特莱茵药品有限公司 | 作为结晶硫酸盐的1-[2-(4-甲苯基-4-羟基-哌啶-1-基)-乙基]-3-(2-甲基-喹啉-4-基)-脲 |
CN101217965A (zh) * | 2005-07-07 | 2008-07-09 | 学校法人浦项工科大学校 | 葡萄糖吸收调节剂和用于治疗糖尿病或糖尿病并发症的方法 |
CN101522197A (zh) * | 2006-07-31 | 2009-09-02 | 詹森药业有限公司 | 尾加压素ⅱ受体拮抗剂 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6936585B2 (en) * | 2002-01-16 | 2005-08-30 | The Procter & Gamble Company | Corticotropin releasing factor 2 receptor agonists |
FR2982488B1 (fr) * | 2011-11-10 | 2013-12-27 | Univ Rouen | Urotensine ii pour son utilisation dans le traitement et/ou la prevention de pathologies impliquant la motilite gastrique |
CN104557618A (zh) * | 2013-10-15 | 2015-04-29 | 南京理工大学 | 一种合成n,n’-二烷基脲的方法 |
CN110038114B (zh) * | 2018-01-15 | 2021-12-07 | 中国医学科学院药物研究所 | 一种多肽在制备预防或治疗代谢综合征药物中的用途 |
-
2018
- 2018-07-27 CN CN201810844111.9A patent/CN110755434B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1494542A (zh) * | 2001-03-27 | 2004-05-05 | ������˹ҩƷ��˾ | 作为尾加压素ii受体拮抗剂的1,2,3,4-四氢异喹啉的衍生物 |
CN101039930A (zh) * | 2004-10-12 | 2007-09-19 | 埃科特莱茵药品有限公司 | 作为结晶硫酸盐的1-[2-(4-甲苯基-4-羟基-哌啶-1-基)-乙基]-3-(2-甲基-喹啉-4-基)-脲 |
CN101217965A (zh) * | 2005-07-07 | 2008-07-09 | 学校法人浦项工科大学校 | 葡萄糖吸收调节剂和用于治疗糖尿病或糖尿病并发症的方法 |
CN101522197A (zh) * | 2006-07-31 | 2009-09-02 | 詹森药业有限公司 | 尾加压素ⅱ受体拮抗剂 |
Non-Patent Citations (2)
Title |
---|
2 型糖尿病与肌萎缩研究进展;王继 等;《中国运动医学杂志》;20170725;第36卷(第7期);第645-650页 * |
2型糖尿病诱导骨骼肌萎缩机制及常用降糖药影响研究进展;梁眉黛 等;《药学学报》;20211012;第1-16页 * |
Also Published As
Publication number | Publication date |
---|---|
CN110755434A (zh) | 2020-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101740893B1 (ko) | Akkermansia muciniphila 균에서 유래하는 세포밖 소포를 유효성분으로 함유하는 대사질환의 치료 또는 예방용 조성물 | |
JP4938905B2 (ja) | 選択的s1p1レセプターアゴニストの投与法 | |
US20080249168A1 (en) | Pharmaceutical composition for gout | |
CN110755434B (zh) | 化合物palosuran防治骨骼肌萎缩等疾病的用途 | |
WO1998015267A1 (en) | Method for the treatment of neurological or neuropsychiatric disorders | |
US6734214B1 (en) | Remedies for diabetes | |
EP2932972B1 (en) | New application of catalpol | |
WO2005049043A1 (en) | Combination therapy comprising metformin and anticonvulsant agents | |
CN110038114B (zh) | 一种多肽在制备预防或治疗代谢综合征药物中的用途 | |
CN110038002B (zh) | 丹酚酸a防治肌肉萎缩、肌病及肌肉骨骼并发症的用途 | |
AU684711B2 (en) | Use of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine for the treatment of pain and oedema | |
KR101671008B1 (ko) | TNP(N2-(m-Trifluorobenzyl), N6-(p-nitrobenzyl)purine) 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 식욕억제용 약학적 조성물 | |
JP5557243B2 (ja) | 睡眠の改善剤 | |
KR102204204B1 (ko) | 근육 질환 예방 및 치료용 조성물 | |
CN110227083A (zh) | 一种含氯化钆和双胍类降糖药的药物组合物及其用途 | |
KR20170079128A (ko) | PPAR-β 길항제를 포함하는 항암 효과 증진용 약학적 조성물 | |
KR102246627B1 (ko) | Hmba를 포함하는 비만 또는 당뇨의 예방 또는 치료용 조성물 | |
CN110420209B (zh) | 一种治疗糖尿病周围神经痛的药物组合物及其应用 | |
US10646466B2 (en) | Uses of gallocatechin | |
WO2022061962A1 (zh) | 一种l型氨基酸转运蛋白抑制剂或拮抗剂有效干预糖尿病的方法 | |
KR102595949B1 (ko) | Ym976를 포함하는 지방세포 분화 억제용 조성물 및 비만의 예방 또는 치료용 조성물 | |
US20060166957A1 (en) | Methods of treating obesity and related disorders using tellurium selenium compounds | |
CN114073706A (zh) | 丹参酮iia磺酸钠在制备药物中的应用 | |
CN116139140A (zh) | 一种化合物在治疗糖皮质激素不良反应中的用途 | |
CN112107581A (zh) | 式i化合物在制备治疗肥胖及相关病症的药中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Du Guanhua Inventor after: Yang Xiuying Inventor after: Chen Xi Inventor after: Qiang Guifen Inventor after: Yin Lin Inventor after: Jia Weihua Inventor after: Wang Nuoqi Inventor after: Zhang Li Inventor after: Hou Biyu Inventor before: Du Guanhua Inventor before: Yang Xiuying Inventor before: Chen Xi Inventor before: Qiang Guifen Inventor before: Yin Lin Inventor before: Jia Weihua Inventor before: Wang Nuoqi Inventor before: Zhang Li Inventor before: Hou Biyu |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant |